Importance of Low- and Moderate-Grade Adverse Events in Patients' Treatment Experience and Treatment Discontinuation: An Analysis of the E1912 Trial.
Nathaniel S O'ConnellFengmin ZhaoJu-Whei LeeEdward Haksing IpJohn Devin PeipertNoah GrahamMary Lou SmithIlana F GareenRuth C CarlosSamilia Obeng-GyasiJoseph A SparanoTait D ShanafeltMary L ThomasDavid CellaLynne I WagnerRobert J GrayPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
Low- and moderate-grade AEs are related to increased odds of increased patient side-effect bother and treatment discontinuation, with symptomatic AEs demonstrating greater magnitude of association than asymptomatic. Our findings suggest that limiting AE capture to grade 3+ misses important contributors to treatment side-effect bother and discontinuation.